Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2021

STOCK-BASED COMPENSATION

Schedule of Accounting for Stock-Based Compensation


		Twelve Months Ended
		December 31,
		2021			2020
Employee and director stock option grants:
Research and development		$	117,805		$	72,579
General and administrative			1,006,385			394,962
Total stock-based compensation		$	1,124,190		$	467,541

Schedule of weighted-average values and assumptions used for stock


		Year Ended December 31,
		2021			2020
Volatility			102.19-104.73	%		96-106	%
Risk-free interest rate			0.81-1.04	%		0.42-1.67	%
Expected life (years)			6			6
Dividend			0	%		0	%
Weighted-average exercise price		$	1.66		$	1.84
Weighted-average grant-date fair value		$	0.94		$	1.42

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


		Number of					Weighted
		Shares					Average
		Issuable Upon		Weighted			Remaining
		Exercise of		Average			Contracted		Aggregate
		Outstanding		Exercise			Term in		Intrinsic
		Options		Price			Years		Value
Outstanding as of December 31, 2019		610,714		$	6.78
Granted		653,750		$	1.84
Forfeited		(80,000)		$	2.46
Outstanding as of December 31, 2020		1,184,464		$	4.34		8.57		$	316,688
Granted		3,537,500		$	1.66
Expired		(41,097)		$	15.48
Forfeited		(442,667)		$	1.71
Outstanding as of December 31, 2021		4,238,200		$	2.27		8.79		$	—

Exercisable as of December 31, 2021		798,238		$	4.82		7.24		$	—
Unvested as of December 31, 2021		3,439,962		$	1.68		9.15		$	—